Download Free Sample
Buy Now
Market Size
The global molecular diagnostics market, valued at USD 17 billion in 2025, is projected to reach USD 18 billion in 2026 and USD 31 billion by 2035, with a 6.4% CAGR during the forecast period 2026 to 2035.
See What’s in the Full Report – Request Your Complimentary Insights!
Market Report: Key Takeaways
Market Size & Trends
- In terms of test type, the laboratory testing segment holds the highest share (85%) of the market.
- With regards to type of offering, the reagents segment dominates the global market with 70% market share.
- Based on the type of sample, the blood, serum and plasma reagents hold the largest market share (nearly 90%) in 2026.
- In terms of type of technology, the PCR segment dominates the global market with more than 40% market share.
- With respect to therapeutic area, infectious diseases segment captures the highest share in 2026.
- With regards to end users, the hospitals segment dominates the global market.
- In terms of geographical regions, North America captures the majority of the market share, and Asia-Pacific is likely to grow at a faster pace in the near future.
Key Market Statistics
- Market Size in 2026: $18 Billion
- Estimated Market Size in 2035: $31 Billion
- CAGR (2026-2035): 6.4%
- North America: Largest market in 2026
- Asia-Pacific: Fastest growing region
Market Overview
Molecular diagnostic tests refer to tests designed to detect specific sequences in human genomic samples, such as DNA or RNA, in order to diagnose a particular disease. Further, such tests also aim to identify single nucleotide polymorphisms, deletions, rearrangements, and insertions in the genetic sequences. It is worth mentioning that molecular diagnostics is a subset of the in vitro diagnostics market.
According to the World Health Organization, over 40,000 in vitro diagnostics products are currently available in the market. This vast array of products highlights the critical role of diagnostics in healthcare. It is worth mentioning that over 70% of the healthcare decisions are made based on laboratory test results, as they provide essential data that informs diagnoses, guide treatment choices, monitor disease progression and assess responses to therapy. This underscores the indispensable role of laboratory professionals and diagnostic testing in ensuring accurate, timely and effective patient care.
Molecular diagnostic tests play a crucial role in diagnosing various diseases, monitoring healthcare responses, and predicting healthcare outcomes. Given the benefits offered by such diagnostic solutions to provide rapid diagnostic results and improve patient outcomes, the global market is likely to grow at a healthy CAGR during the forecast period. This molecular diagnostics market growth is due to several factors, including the growing demand for point of care diagnostics devices, rapid diagnostics testing, and the increasing prevalence of infectious diseases.
In conclusion, the molecular diagnostics industry is likely to demonstrate robust growth, driven by technological advancements, increasing prevalence of infectious and chronic diseases, and a growing emphasis on personalized medicine. As innovations in genomics and point-of-care testing continue to emerge, the market is likely to witness expanded applications and improved accessibility, worldwide. Ultimately, molecular diagnostics will play an increasingly vital role in transforming disease detection, patient management and overall healthcare outcomes in the years ahead.
Recent Developments in Molecular Diagnostics Market
- In March 2026, Insight Molecular Diagnostics completed key milestones for GraftAssureDx test, including a three-site reproducibility study at Tampa General Hospital, Mayo Clinic, and Baylor Scott & White Health.
- In March 2026, Ontario government provided $1.1 million funding through NOHFC to RNA Diagnostics in Sudbury for VeriDART cancer diagnostic technology research.
- In September 2025, Illumina collaborated with multiple global pharmaceutical companies to develop companion diagnostics for KRAS alterations using TruSight Oncology comprehensive genomic profiling test, advancing personalized cancer care by targeting uncontrolled cell growth leading to cancer.
Pay Only for What You Need – The Best Way to Optimize
Molecular Diagnostics Market Trends
- Rising Key Development Efforts Amongst the Industry Stakeholders to Foster Progress and Innovation in Expanding their Capabilities: Stakeholders in this domain have entered into numerous partnerships and collaborations, allowing them to expand their respective offerings and enhance their capabilities and visibility. Notably, in the last few years, companies across various geographies have inked multiple partnerships to strengthen their molecular diagnostics capabilities.
In June 2025, Tracer Biotechnologies announced a strategic partnership with QIAGEN to co-develop and commercialize minimal residual disease (MRD) assays for solid tumors on QIAGEN’s QIAcuity digital PCR platform. This collaboration aims to deliver highly sensitive, cost-effective, and decentralized MRD testing solutions that enable oncologists to monitor cancer recurrence and guide personalized treatment decisions using minimally invasive blood samples.
- Technological Advancements to Fuel Innovation and Drive Efficiency: Recent technological advancements in molecular diagnostics are transforming disease detection and patient care by enabling faster, more accurate and more personalized testing. A range of novel molecular diagnostic tests are also being developed for rapid, sensitive and specific molecular detection for diagnosing, treating and prognosing cancer patients.
Additionally, recent advances in molecular allergology have transformed allergy diagnostics through innovative approaches in allergen characterization, including allergen structure and biomarker identification. Component-resolved diagnosis (CRD) has reduced misdiagnosis rates by 40% in pollen-food syndrome cases, by distinguishing primary sensitizations from cross-reactivity. These advances in molecular diagnostics support allergen immunotherapy (AIT) decisions, particularly for complex polysensitizations, and facilitate the development of new forms of immunotherapy.
Market Share Insights
Market Share by Type of Sample: Blood, Serum and Plasma Segment to Hold the Highest Market Share
- This segment highlights the distribution of market for molecular diagnostics across various types of samples, such as blood, serum and plasma, urine and others.
- In 2026, blood, serum and plasma segments are likely to capture more than 75% of the overall market share, owing to its widespread use in detecting infectious diseases, cancer biomarkers and genetic conditions.
- It is worth highlighting that the market for urine segment is likely to grow at a relatively higher CAGR (7.0%), during the forecast period. This is a result of recent attraction towards urine sampling, particularly in detecting urological cancers and infectious diseases, due to their non-invasive nature.
Market Share by Test Type: Laboratory Testing Segment Holds the Largest Market Share
- This segment highlights the distribution of market value for molecular diagnostics across laboratory testing and point-of-care testing.
- In 2026, the laboratory testing segment occupies the higher market share (85%) and this trend is unlikely to change in the future.
- It is worth mentioning that the point-of-care testing segment is likely to grow at a relatively higher (9.1%), during the forecast period, owing to their ability to deliver rapid test results and offer improved accessibility.
Market Share by Type of Offering: Reagents Segment to Dominate the Overall Market
- This segment highlights the distribution of global molecular diagnostics market across various types of offerings such as reagents, instruments and services.
- Among these types of offerings, the reagents segment occupies the highest market share (70%) in 2026. This is due to the fact that reagents are required to be replenished frequently, generating a continuous flow of revenue.
- Further, the market for instruments segment is likely to grow at a relatively higher CAGR (6.6%), during the forecast period due to their recurring demand and technological advancements for efficient and accurate diagnostic procedures.
Market Share by Type of Technology: Next Generation Sequencing Segment to Grow at a Higher CAGR
- Based on the type of technology, the overall market includes polymerase chain reaction (PCR), in situ hybridization, isothermal nucleic acid amplification technology, next generation DNA sequencing, microarrays, mass spectrometry and other types of technologies.
- In 2026, polymerase chain reaction (PCR) segment captures more than 40% of the overall market share, owing to its accuracy, speed, and widespread application in diagnosing infectious diseases, genetic disorders, and cancer.
- However, the next generation sequencing segment is likely to grow at a higher CAGR of 7.3% during the forecast period, which is most likely to be driven by its ability to provide comprehensive genomic information and advance personalized medicine.
Market Share by Therapeutic Area: Infectious Diseases Segment to Dominate the Overall Market
- Based on the therapeutic area, the overall market includes infectious diseases, oncological disorders, cardiovascular diseases, neurological diseases, genetic diseases and other disorders.
- According to our molecular diagnostics market report, in 2026, infectious diseases segment captures more than 40% of the overall market share, owing to the increasing prevalence of various respiratory infections, such as influenza, respiratory syncytial virus (RSV), and pneumonia.
- Further, the neurological diseases segment is likely to grow at a higher CAGR of 6.9% during the forecast period, owing to the advancements in understanding the genetic and molecular basis of neurological conditions, leading to more accurate and early diagnoses, personalized treatment plans and the identification of potential therapeutic targets.
Market Share by End User: Laboratories Segment to Grow at a Higher CAGR
- Based on the end user, the overall market includes hospitals, laboratories and other end user.
- In 2026, hospitals segment captures around 50% of the overall market share and is likely to grow at a relatively higher CAGR, during the forecast period.
- This is due to the fact that a high volume of diagnostic tests are performed in-house for patient management and immediate diagnostic results for critical conditions within the hospital-settings.
Market Share by Geographical Regions: Asia to Propel in the Molecular Diagnostics Sector in the Coming Years
- This segment highlights the distribution of global market across various geographical regions, such as North America, Europe, Asia, Latin America, Middle East and North Africa, and rest of the World.
- According to our projections, North America is likely to capture the majority (~40%) of the molecular diagnostics market share in 2026, and this trend is unlikely to change in the future.
- It is worth highlighting that the market in Asia is likely to grow at a relatively higher CAGR (6.5%), during the forecast period. This is a result of the increasing prevalence of both infectious and chronic diseases, a rapidly aging population and significant technological advancements in diagnostic methods.
Want Information on Specific Region / Segment?
Key Market Insights
Molecular Diagnostics Companies Competitive Landscape
The current market landscape features more than 100 companies including very large, large, mid-sized and small companies. These companies have the required expertise to develop and provide molecular diagnostic solutions, across different geographical regions.
Notably, North America features the presence of 55% of the molecular diagnostic solutions providers, followed by Europe (30%). In addition to this, close to 90% of the companies offer next generation sequencing technologies, followed by microarrays (85%) and mass spectrometry (80%).
Market Size Analysis: Global Market to Grow at High CAGR
The global molecular diagnostics market size is likely to be worth USD 18 billion in 2026 and will reach USD 31 billion by 2035. In terms of the sample type, the global market is categorized into blood, serum and plasma, urine and others. In 2026, the blood, serum and plasma segment dominates the market and holds 80% of the market share, owing to its widespread use in detecting infectious diseases, cancer biomarkers and genetic conditions.
Further, the market size for urine samples segment is likely to grow at a relatively higher CAGR of 7.0 % during the forecast period. The improved sensitivity, faster turnaround times and non-invasiveness are the primary drivers of this market segment. Additionally, owing to the growing interest in personalized healthcare and rising prevalence of chronic and infectious diseases around the globe, we believe that the global molecular diagnostics industry is likely to grow at a steady rate during the forecast period.
Have Questions? Let’s Get Them Answered.
Regional Analysis: Which Region Holds the Largest Molecular Diagnostics Market Share?
North America is Leading the Market
North American companies will likely dominate the global molecular diagnostics market in 2035, owing to the robust research and development activities, coupled with increasing demand for molecular diagnostics and personalized medicines.
Asia-Pacific: An Emerging Growth Spot
The market in Asia-Pacific is likely to grow at a relatively high CAGR (6.5%), during the forecast period till 2035. This is a result of increased healthcare spending and government initiatives to improve healthcare infrastructure, alongside a surge in demand for personalized medicine and companion diagnostics development, in this region.
Market Drivers: Growing Shift Towards Personalized Healthcare and Increasing Prevalence of Chronic Diseases
- The growing interest in personalized healthcare is a significant driver of the molecular diagnostics market. Molecular diagnostics play a crucial role in this paradigm by providing genetic and molecular insights that enable tailored treatment approaches. Further, advanced molecular diagnostic technologies, such as PCR and next-generation sequencing, are at the forefront of this transformation as these technologies facilitate comprehensive genetic analysis and enable the identification of mutations associated with various diseases.
- It is worth mentioning that the application of molecular diagnostics for chronic diseases in facilitating early detection and personalized treatment is becoming increasingly vital. This evolution not only enhances patient care but also supports public health initiatives aimed at controlling and preventing disease outbreaks.
Market Challenges: Data Security Concerns May Hinder the Growth
- Despite their several benefits, the use of molecular diagnostics presents several challenges. One of the most significant issues is the shortage of skilled workforce. Further, the integration of external data sources, such as patient health records, genomic data and real-world healthcare results requires advanced data management infrastructure and cybersecurity measures in order to protect patient’s privacy and ensure data security and compliance.
Market Segmentation Insights
| Key Report Attributes | Details | |
| Historical Trend | Since 2018 | |
| Forecast Period | Till 2035 | |
| Market Size 2026 | $ 18 Billion | |
| Market Size 2035 | $ 31 Billion | |
| CAGR (Till 2035) | 6.4% | |
| Test Type |
|
|
| Type of Offering |
|
|
| Type of Sample |
|
|
| Type of Technology |
|
|
| Therapeutic Area |
|
|
| End User |
|
|
| Geographical Regions |
|
|
| Excel Data Packs (Complimentary) |
|
|
| Key Players |
A complete list of more than 100 companies is available in the report |
|
| PowerPoint Presentation (Complimentary) | Available | |
| Customization Scope | 15% Free Customization | |
